Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Open in API
Filings indexed 1,096 across all filing types
Latest filing 2016-07-29 Annual Report
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
FORM 10-K
Annual Report FY 2016
2016-07-29 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 26, 2016, reporting the issuance of a press release announcing consolidated financial results for the fourth quarter and full fiscal year ended May 29, 2016. The text states that the press release is furnished as Exhibit 99.1 and that the information is being furnished, not filed, and is not incorporated by reference elsewhere. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of financial results via a press release. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. The document length is 3144 characters, which is short and consistent with an 8-K filing announcing earnings results rather than a full report. Therefore, the correct classification is Earnings Release (ER).
2016-07-26 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the approval of performance criteria for employee cash bonuses and the grant of stock options and restricted stock units to the CEO. This corresponds to announcements about changes in management compensation and appointments. The key section is Item 5.02, which relates to departure or election of directors or officers and compensatory arrangements. This fits the category of Board/Management Information (MANG). The document is not a full annual or quarterly report, nor is it an earnings release or proxy statement. It is a regulatory filing but more specifically about management changes and compensation, so MANG is the best fit. The document length is under 5,000 characters but contains substantive information about management decisions, not just an announcement of a report, so it is not RPA or RNS. Confidence is high due to clear SEC form type and content focus.
2016-07-26 English
FORM 4
Director's Dealing
2016-07-25 English
FORM 4
Director's Dealing
2016-06-09 English
FORM 4
Director's Dealing
2016-06-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.